David T. Curiel

发表

CAR-Independent Gene Transfer to Accomplish Efficient and Specific Genetic Modification of Target Cells Via Adenoviral Vectors

David T. Curiel, 1999, Nature Biotechnology.

AdenoLibrary approach for vector construction and selection of targeted adenoviruses employing novel fiber-fibritin chimeric fibers

David T. Curiel, Sam C. Noureddini, Alexander Krendelshchikov, 2005 .

Incremental advances and radical paradigm shifts

David T. Curiel, 1999 .

Vector Targeting for Therapeutic Gene Delivery

David T. Curiel, Joanne T. Douglas, D. Curiel, 2002 .

Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9

David T. Curiel, D. Curiel, Lyudmila Kaliberova, 2018, Gene Therapy.

Long‐term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9

David T. Curiel, Wayne M. Yokoyama, D. Curiel, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Corneal avascularity is due to soluble VEGF receptor-1

J. Martin Collinson, Eiji Sakurai, Tushar Suthar, 2006, Nature.

Engineering targeted viral vectors for gene therapy

David T. Curiel, Stephen J. Russell, D. Curiel, 2007, Nature Reviews Genetics.

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection

Saul Tzipori, David T. Curiel, Gillian Beamer, 2016, Clinical and Vaccine Immunology.

Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis

Matthew Cotten, Ernst Wagner, David T. Curiel, 1994 .

The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.

David T. Curiel, Joanne T. Douglas, Myunghee Kim, 2002, European journal of cancer.

A One Health overview, facilitating advances in comparative medicine and translational research

Dongsheng Duan, Ubadah Sabbagh, James P. Calvet, 2016, Clinical and Translational Medicine.